Medincell (XPAR:MEDCL) Short-Term Capital Lease Obligation : €0.64 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Short-Term Capital Lease Obligation?

Medincell's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.64 Mil.

Medincell's quarterly Short-Term Capital Lease Obligation increased from Sep. 2022 (€0.63 Mil) to Mar. 2023 (€0.64 Mil) but then declined from Mar. 2023 (€0.64 Mil) to Sep. 2023 (€0.64 Mil).

Medincell's annual Short-Term Capital Lease Obligation increased from Mar. 2021 (€0.39 Mil) to Mar. 2022 (€0.58 Mil) and increased from Mar. 2022 (€0.58 Mil) to Mar. 2023 (€0.64 Mil).

Medincell Short-Term Capital Lease Obligation Historical Data

The historical data trend for Medincell's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Short-Term Capital Lease Obligation Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.06

0.32

0.39

0.58

0.64

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial										0.44	0.58	0.63	0.64	0.64

Medincell Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Medincell Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Medincell's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines